{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-24-000038","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.083657+00:00","generated_at":"2026-05-31T13:51:59.552066+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Shattuck Labs Q2 net loss $21.5M; SL-172154 shows 67% ORR in HR-MDS trial","bullets":["Net loss $21.5M ($0.42 per share) vs $21.3M ($0.50 per share) Q2 2023.","Cash and investments $105.3M as of June 30, 2024, down from $117.2M a year ago.","SL-172154 in frontline HR-MDS: 67% ORR, 58% CR/marrow CR rate; median OS not reached.","Randomized Part D enrollment initiated in frontline HR-MDS (1:1:1 vs AZA alone).","Cash runway into 2026, beyond Phase 1 trial results."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-24-000038","json":"https://secwatch.observer/filing/0001680367-24-000038.json","markdown":"https://secwatch.observer/filing/0001680367-24-000038.md","text":"https://secwatch.observer/filing/0001680367-24-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036724000038/0001680367-24-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036724000038/sttk-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:51:59.552066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}